The mission of Crossbow Therapeutics is to cure cancer. Their team is developing highly potent and accurate antibody-based therapies to target tumor-specific peptides. They are developing next-generation immunotherapies, called T-Bolt therapies, utilizing T cell receptor-memetic antibodies. Crossbow was founded in 2021 by co-founders Geraldine Paulus, Patrick Baeuerle, and Todd Foley.

Crossbow Therapeutics

Newco trend watch: Clusters of launches point to areas undergoing derisking - BioCentury

If you are attending the annual American Society of Hematology meeting, we invite you to come to our oral presentation, where we'll discuss the #IND-enabling characterization of Crossbow Therapeutics, Inc's first program, CBX-250, a TCR-mimetic-based T Cell Engager targeting a Cathepsin G peptide-HLA complex, for the treatment of #AML and other heme malignancies.
#ASH2024
Details below. 

A South Korean investment firm starts first US biotech fund - BioPharma Dive

Crossbow Therapeutics, Inc.,

 BioSpace Names Most Promising New Biopharma Companies to Watch in 2024 

Crossbow arms itself with $80 million for mission to cure cancer - The Pharma Letter

 Crossbow Therapeutics raises series A funding to develop therapies based on TCR mimetics 

Crossbow nominates T-cell engager CBX-250 as development candidate for myeloid leukemia - BioWorld Online

Crossbow targets cancer with T-Bolt molecules and $80M series A - BioWorld Online

Introducing the newest members of Crossbow Therapeutics, Inc! Please join us in welcoming Brendan Whalen to the #Antibody Discovery, #Protein Engineering, and #ProcessDevelopment (ADPEPD) team and Emily McNally to the #Biology group. We are confident that their experience will move us towards our mission of broadening the benefits of #immunotherapy and improving the lives of people living with #cancer.

We are #hiring at Crossbow Therapeutics, Inc! Our head of Regulatory Affairs and Clinical Development Operations, Shaliny Kushwaha, is looking to bring on board a Senior Director/Head of Quality Assurance to join our innovative and collaborative team. Find out more about the position and how to apply in the job posting below.

#cancer #immunooncology #quality #QA 

The Week’s 10 Biggest Funding Rounds: Biotech Dominates As Septerna Raises $150M - Crunchbase News

Welcoming the newest members of Crossbow Therapeutics, Inc!  We'd like to introduce you to qunyan yu in the #Translational Medicine Team and Megan McLaughlin, CPM in Corporate Operations and #ProgramManagement. We are confident that their experience will move us towards our mission of broadening the benefits of #immunotherapy and improving the lives of people living with #cancer.

www.crossbowtx.com

 Geraldine Paulus on LinkedIn: #aacr2024 #tce #aml #cancer #immunotherapy 

Our head of #translational #medicine Benjamin Lee did a terrific job highlighting the characteristics of CBX-250, our differentiated T Cell Engager for the treatment of #AML and other heme malignancies at #ASH2024 earlier today! 
#TCE #oncology #TCRmimetic #antibody #heme 

We're #hiring! Come join my team at Crossbow Therapeutics, Inc! This is an exciting role spanning #ProgramManagement, #RnDOperations, #CorporateOperations, competitive intelligence and more! We're a dynamic, collaborative and innovative #biotech team that is boldly pushing to bring new #medicines to patients. If this sounds like a match, don't hesitate to #apply!

Say hello to the newest members of the #Finance team at Crossbow Therapeutics, Inc. We are delighted to welcome Anita Valente, CPA and Tatiana Vales. Their contributions will keep us on target as we collectively work towards our mission of broadening the benefits of #immunotherapy and improving the lives of people living with #cancer.

 Crossbow Therapeutics, Inc on LinkedIn: Today, Crossbow Therapeutics, Inc is presenting data on our first… 

The Crossbow Therapeutics, Inc team enjoying its summer outing on the Charles River on a beautiful afternoon! It’s always a great to take time to socialize and have some fun together.
Special thanks to Sarah Jaffe for making this happen!!

 Crossbow nominates T-cell engager CBX-250 as development candidate for myeloid leukemia 

We are #hiring at Crossbow Therapeutics, Inc! Our Co-founder, VP of Corporate Development and Operations, Geraldine Paulus, is looking to bring on board an exciting new role as a senior manager or associate director, corporate operations and program management. Find out more about the position and how to apply in the Job Posting below.

Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics - Pharmaceutical Technology Magazine

 Crossbow reports preclinical data on first development candidate 

Crossbow Therapeutics, Inc. announced that it has received $80.000001 million in funding from a group of investors - Marketscreener.com

We are delighted to announce that Dr. Charles Baum, MD, PhD has joined Crossbow Therapeutics, Inc's #board as an independent director. Chuck is an accomplished #biopharma exec who brings over 30 years of experience in #oncology and we look forward to benefitting from his deep expertise.

You can find his full bio on our website's team section: https://lnkd.in/euQ2u9Fp

 Crossbow targets cancer with T-Bolt molecules and $80M ... 

Briggs Morrison helms new MPM oncology startup with Pfizer Ventures, Polaris partners on board - Endpoints News

Crossbow Therapeutics

Business:

About: